Actively Recruiting
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
Led by First Hospital of China Medical University · Updated on 2024-10-08
84
Participants Needed
1
Research Sites
67 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.
CONDITIONS
Official Title
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of hepatocellular carcinoma (HCC) confirmed by radiology, histology, or cytology
- BCLC stage C with portal vein tumor thrombus present
- Previous systemic therapy recommended by BCLC for HCC has failed
- Use of marketed PD-1 inhibitors and Lenvatinib, not limited to HCC approval
- HAIC performed either before or after first PD-1 inhibitor/Lenvatinib treatment
- Received at least 2 cycles of HAIC
- Presence of repeated measurable intrahepatic lesions
- Child-Pugh class A or B
You will not qualify if you...
- More than 3 months between failure of systemic therapy and start of combination therapy
- Presence of other malignant tumors
- Unable to meet the combination therapy timing criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The first hospital of China medical university
Shenyang, Liaoning, China, 110000
Actively Recruiting
Research Team
J
Jiaxi Liu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here